Eli Lilly, also known as Lilly, a wholly-owned subsidiary of Eli Lilly and Company, and Cipla announced its strategic partnership in India to enhance the reach of Lilly’s diabetes products – Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide).

As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute two Lilly diabetes products – Humalog & Trulicity to Cipla, subject to all regulatory approvals.

Lilly will continue to maintain its existing operating model for the remaining portfolio of products.

Cipla will leverage its capabilities and robust distribution strengths to engage healthcare professionals and expand access to these treatments for patients who need them.

Commenting on the partnership, Luca Visini, Managing Director India Subcontinent, Lilly India, said, we are proud to be announcing our partnership with Cipla, which, pending full regulatory approvals, will hold the rights to sell, market, and distribute select Lilly diabetes portfolio products. Cipla has a strong local footprint and is well established to expand access to those medicines around India.”

Dr. Vikas Gupta, Head, India Prescription Business, Cipla said, “We are pleased to collaborate and build onto our existing partnership with Lilly India towards bringing innovative diabetes medications to India.’’